Today Cannabis Science Releases Updates To Its Website That Integrates General Public Communications With Recent Developments In Its Analytical, Clinical Research, and Commercial Production Divisions
COLORADO SPRINGS, Colo. -- Cannabis Science Inc. (NASD OTCBB: CBIS), an emerging pharmaceutical cannabis company, released updates to its website today. The website www.cannabisscience.com now integrates its general public communications with recent and future developments in its analytical lab work, clinical research, and commercial production division that are in the process of formalizing the agreements with all the necessary contractors in order to move forward with its medical cannabis clinical trails.
The updated website includes new tools that allow its analytical, clinical research, and commercial production divisions to communicate with the medical cannabis community, survey specific populations, and receive feedback from patients, partners, and investors. The information gathered through its site surveys and forums will help guide its clinical research as well as contribute to scientific databases, and our live blog will allow the community to check in on its progress.
This two-way communication keeps the medical movement and Cannabis Science at the forefront of allowing discovery of the best ways to provide medical cannabis patients with what they need. Specifically, the confidential PTSD survey been launched with the website today allowing data input from patients that will later influence PTSD clinical trials. Please visit to fill out your experiences with PTSD and Cannabis medicines.
Cannabis Science Inc., President & CEO, Dr. Robert Melamede, Ph.D., stated, " We have made good progress with our analytical lab work, and most importantly we now have open dialogue with an integral part of our business model-the patients. Our genetic and biochemical research is now allowing us to move towards utilizing several unique technologies in the propagation of stable, carefully selected strains of medical cannabis that we will use in our formulations to target specific illnesses such as PTSD, influenza, chronic pain and inflammation, etc. Our efforts along with the amalgamation of the analytical lab results and the ability of the Clinical Research Division to gather patient cohort data will result in an efficient, quality-controlled method of production of medical cannabis that will allow the formulation of Cannabis Science's cannabis pharmaceutical products for clinical testing."
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.
Forward Looking Statements: This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.